Skip to content
eXoZymes, Inc. logo

eXoZymes, Inc.

EXOZ

eXoZymes Inc. is a biotechnology company specializing in a proprietary cell-free biomanufacturing platform that utilizes AI-designed enzymes to produce high-value chemicals.

Market cap
$65.71M-21.6%
Net income-$9.7M-44.2%
Free cash flow-$7.1M+30.5%
EPS (diluted)-$1.14-18.8%
Trailing twelve months · change vs. prior year

Earnings

Q1 2026 report

May 14, 2026

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation & ratios

Valuation

See full
Market cap$65.71M-21.6%
Enterprise value$65.48M-17.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Competitors

Profile

eXoZymes Inc. is a biotechnology company specializing in a proprietary cell-free biomanufacturing platform that utilizes AI-designed enzymes to produce high-value chemicals. The company's core value proposition lies in its ability to bypass the scalability and toxicity limitations of traditional synthetic biology by engineering complex biochemical pathways outside of living cells. This approach enables the sustainable and cost-effective production of natural products for the pharmaceutical, nutraceutical, and biofuel industries.

Competitive position

eXoZymes positions itself as a technological successor to synthetic biology, offering a more controllable and scalable cell-free platform for complex multi-step enzymatic conversions.

GeographiesUnited States, Global
Customer segmentsPharmaceutical Developers, Nutraceutical Brands, Energy and Fuel Corporations
Business modelIP Licensing, Joint Venture, Research and Development Services, B2B Ingredient Supplier
SuppliersIndustrial microbial hosts (E. coli, P. pastoris), Low-cost feedstocks, AI and bioengineering software, Laboratory equipment providers
CustomersContract Manufacturing Organizations (CMOs), Pharmaceutical manufacturers, Nutraceutical distributors, Biofuel blenders
Listed2024
CEOMichael Heltzen
FilingsSEC EDGAR

Questions, answered.

What is eXoZymes, Inc.'s market cap?
eXoZymes, Inc. (EXOZ) has a market capitalization of $65.7M and trades on NASDAQ.
Who are eXoZymes, Inc.'s competitors?
eXoZymes, Inc.'s key competitors include Gevo, Inc., Codexis, Inc., Ginkgo Bioworks, and others. These companies compete in similar markets and product categories.
Who does eXoZymes, Inc. partner with?
eXoZymes, Inc.'s notable partners include The Regents of the University of California, Bill & Melinda Gates Foundation, Shell, and others.
What subsidiaries does eXoZymes, Inc. have?
eXoZymes, Inc.'s subsidiaries include NCTX.
Where is eXoZymes, Inc. headquartered?
eXoZymes, Inc. is headquartered in United States of America. It has been publicly traded since 2024.